ReviewThe Lancet. Haematology2020
Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.
Review in The Lancet. Haematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 60 citations in OpenAlex.
- Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study.Blood advances · 2023Trial
- Cardio-Oncological Sequelae of Autologous Stem Cell Transplantation: Role of Clonal Hematopoiesis in Cardiovascular Risk.JACC. Advances · 2026Article
- A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions.Nature reviews. Clinical oncology · 2026Review
- Genetic Findings of Potential Donor Origin in Cells Used for Cell and Gene Therapy: Recommendations from the World Marrow Donor Association.Transplantation and cellular therapy · 2026Review
- CHIP ahoy: charting a decade of discovery in clonal hematopoiesis.Haematologica · 2026Review
- CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.Research square · 2025Article
- Low Allele Frequency Variants Identified on Germline Multi-Gene Panel Testing for Cancer Predisposition Can Suggest the Presence of Constitutional Mosaicism.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Understanding residual risk of cardiovascular disease in people with HIV.Current opinion in HIV and AIDS · 2025Review
- Genome sequencing in the management of myelodysplastic syndromes and related disorders.Haematologica · 2025Review
- Clonal hematopoiesis and atherosclerosis.The Journal of clinical investigation · 2024Review
- Real-World Impact of Deep Targeted Sequencing on Erythrocytosis and Thrombocytosis Diagnosis: A Reference Centre Experience.Cancers · 2024Article
- Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study.Blood neoplasia · 2024Article
- A cross-sectional study using the Surveillance, Epidemiology, and End Results Program database to estimate the prevalence of Myelodysplastic syndrome (MDS) in the United States.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024Article
- Psychological toxicity in classical hematology.European journal of haematology · 2023Review
- Artificial intelligence to empower diagnosis of myelodysplastic syndromes by multiparametric flow cytometry.Haematologica · 2023Article
- Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions.Blood advances · 2023Article
- Prediction of risk for myeloid malignancy in clonal hematopoiesis.NEJM evidence · 2023Article
- Increased clonal hematopoiesis involving DNA damage response genes in patients undergoing lung transplantation.JCI insight · 2023Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Diagnosing, surveilling, and understanding the biological consequences of clonal haematopoiesis poses a clinical challenge for both patients and clinicians. The relationship between peripheral blood cytopenias and myeloid neoplasms-such as myelodysplastic syndrome-is an area of active research, and understanding of clonal haematopoiesis has developed markedly on the basis of findings concerning somatic mutations in genes known to be associated with myelodysplastic syndrome. These findings have raised the conundrum of how to appropriately define and follow myelodysplastic syndrome precursor states, such as clonal haematopoiesis of indeterminate potential (CHIP) and clonal cytopenias of undetermined significance (CCUS). Identifying these conditions could allow earlier diagnosis of myelodysplastic syndrome, modify surveillance for myelodysplastic syndrome, and possibly guide therapies, but this information also comes at a cost to patients that might or might not be justified by our present understanding of clonal haematopoiesis. When faced with a diagnosis of clonal haematopoiesis, some patients and providers might be content to let the events unfold naturally, whereas others may insist on intense follow-up and early interventions. This Viewpoint assesses recent developments in clonal haematopoiesis and the related implications for affected patients and their providers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.